Cingulate's (CING) shares rose nearly 19% in recent Monday trading after the company said it raised $5 million through a financing deal with an accredited investor.
The transaction involved a non-convertible, unsecured promissory note for nearly $5.5 million, with a 9% annual interest rate and an 18-month maturity, the company said.
Net proceeds will be used for working capital and general corporate purposes, the company said, adding that this capital will support clinical, manufacturing, regulatory activities, and operating costs into Q4 2025. The company aims to file the new drug application for potential approval of CTx-1301 by mid-2025.
Price: 4.94, Change: +0.84, Percent Change: +20.37
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。